Novartis significantly reducing RNAi development efforts, FierceBiotech says Novartis confirmed it plans to "significantly reduce" its RNAi research efforts, the company told FierceBiotech in a statement, adding that its decision was "driven by ongoing challenges with formulation and delivery and the reality that the current range of medically relevant targets where siRNA may be used is quite narrow." Reference Link
News For NVS From The Last 14 Days
Check below for free stories on NVS the last two weeks.
Novartis treatment for pigmented villonodular synovitis gets orphan designation According to a post on the FDA's website, Novartis' recombinant human monoclonal antibody of the IgG1 kappa class against human macrophage colony-stimulating factor received orphan designation. Reference Link